（ 二 ） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 成都苑东生物制药股份有限公司（以下简称"公司"）已于 2024 年 10 月 25 日发布公司 2024 年第三季度报告，为加强与投资者的深入交流，使投资者更加 全面、深入地了解公司 2024 年第三季度的经营成果、财务指标等情况，公司计 划于 2024 年 11 月 18 日（星期一）上午 10:00-11:00 举行 2024 年第三季度业绩 说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2024 年 11 月 18 日（星期一）上午 10:00-11:00 证券代码：688513 证券简称：苑东生物 公告编号：2024-080 成都苑东生物制药股份有限公司 关于召开 2024 年第三季度业绩说明会的 ...

证券代码：688513 证券简称：苑东生物 公告编号：2024-079 成都苑东生物制药股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/8/15 | | --- | --- | | 回购方案实施期限 | 2023/8/15~2025/2/14 | | 预计回购金额 | 10,000 万元~20,000 万元 | | 回购用途 | 用于员工持股计划或股权激励 | | 累计已回购股数 | 股 3,316,769 | | 累计已回购股数占总股本比例 | 1.8788% | | 累计已回购金额 | 万元 12,369.42 | | 实际回购价格区间 | 28.12 元/股~56.05 元/股 | 一、 回购股份的基本情况 2023 年 8 月 14 日，公司召开第三届董事会第十一会议审议通过了《关于以集 中竞价交易方式回购股份方案的议案》，公司拟使用人民币 10,000 万元（含）至 20,000 万元（含）自有资金回购公司股 ...

公 司 研 究 2024 年 10 月 30 日 公司点评 买入/维持 苑东生物(688513) 昨收盘:34.65 医药 苑东生物：近年获批新品放量，制剂业务快速增长 走势比较 (30%) (20%) (10%) 0% 10% 20% 23/10/3024/1/1124/3/2424/6/524/8/1724/10/29 苑东生物 沪深300 股票数据 总股本/流通(亿股) 1.77/1.77 总市值/流通(亿元) 61.17/61.17 12 个月内最高/最低价 (元) 64.25/28.11 相关研究报告 <<苑东生物中报点评：国内制剂贡献 增量，驱动收入快速增长>>--2024- 08-21 <<苑东生物：麻醉镇痛领域差异化布 局，特色解毒剂开启国际化>>-- 2024-06-02 证券分析师：谭紫媚 电话：0755-83688830 E-MAIL：tanzm@tpyzq.com 分析师登记编号：S1190520090001 证券分析师：张懿 电话：021-58502206 E-MAIL：zhangyi@tpyzq.com 分析师登记编号：S1190523100002 事件：2024 年 10 月 2 ...

证券代码：688513 证券简称：苑东生物 成都苑东生物制药股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown impressive performance with a revenue of 1.04 billion yuan in Q1-Q3 2024, representing a year-on-year increase of 22.38%. The net profit attributable to shareholders reached 217 million yuan, up 12.03% year-on-year [4] - The company is focused on the anesthesia and analgesia sector, with strong market competitiveness and leading market shares in several key products [5] - The company is expanding its overseas business, with recent FDA approvals for its products, which opens up significant growth opportunities [6] Financial Performance Summary - For Q1-Q3 2024, the company reported a gross margin of 77.55% (down 3.63 percentage points) and a net margin of 20.87% (down 1.93 percentage points) [4] - The company has forecasted net profits for 2024-2026 to be 272 million, 331 million, and 403 million yuan respectively, with corresponding EPS of 1.54, 1.87, and 2.28 yuan [4] - The current price-to-earnings (P/E) ratios are projected to be 23.8, 19.6, and 16.1 for the years 2024, 2025, and 2026 respectively [4] Market Position and Product Development - The company’s products, including various injection solutions, rank among the top three in market share according to data from the Minet network [5] - The company is actively advancing its product pipeline, with new products receiving regulatory approvals in 2024 [5][6] Growth Potential - The company’s recent FDA approvals for its products mark a significant step in its international expansion strategy, which is expected to contribute to substantial revenue growth [6]

Investment Rating - The report maintains a "Recommended" investment rating for the company [1][6]. Core Views - The company has accelerated its main business growth, with a revenue of 1.04 billion yuan in the first three quarters of 2024, representing a year-on-year increase of 22.38%. The net profit attributable to the parent company reached 217 million yuan, up 12.03% year-on-year [3][6]. - The company is expected to continue benefiting from its innovative pipeline and international expansion, with significant catalysts anticipated in the near term [3][6]. Financial Summary - For the first three quarters of 2024, the company achieved a revenue of 1.04 billion yuan (+22.38%) and a net profit of 217 million yuan (+12.03%). The net profit after deducting non-recurring items was 168 million yuan (+14.92%), with a year-on-year growth of 21.85% after excluding stock incentive expenses [3][6]. - In Q3 2024, the company reported a revenue of 370 million yuan (+25.81%) and a net profit after deducting non-recurring items of 54 million yuan (+16.72%), with a year-on-year growth of 31.64% after excluding stock incentive expenses [3][6]. - The company’s revenue projections for 2024-2026 are 1.45 billion yuan, 1.82 billion yuan, and 2.27 billion yuan, respectively, with net profit expectations of 289 million yuan, 364 million yuan, and 457 million yuan [4][6]. - The company’s gross margin is projected to be around 79.7% in 2024, with a net margin of 19.9% [4][6]. Innovation and Internationalization - The company is advancing its innovative pipeline, with promising data from the Phase III clinical trial of its small molecule drug, and plans to submit a New Drug Application (NDA) for its morphine and naloxone sustained-release capsules in the second half of 2024 [3][6]. - The company is focusing on internationalizing its formulations, particularly in the opioid detoxification and emergency medication sectors, with two products receiving FDA approval for the U.S. market [3][6].

成都苑东生物制药股份有限公司 2024 年第三季度报告 单位：元 币种：人民币 证券代码：688513 证券简称：苑东生物 成都苑东生物制药股份有限公司 2024 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 （一） 主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------------|--------------------------------------|----------------|---------- ...

Investment Rating - The report assigns an "Accumulate" rating to the company [2] Core Viewpoints - The impact of centralized procurement is gradually clearing, and new formulations are expected to continuously contribute to performance growth. The company's existing key products have been included in centralized procurement, and the negative impact of price reductions on performance has been fully digested. Revenue is expected to maintain steady growth based on stable prices and increased volume. Additionally, the number of approved formulations has significantly increased, with several products showing good potential for volume growth. The company is focusing on analgesic and anesthetic products, developing specialized drugs with technical barriers and policy thresholds, which will help form new performance growth drivers [6][12]. - The export product lineup is continuously enriching, and revenue is expected to enter a rapid growth phase. The company is focusing on opioid detoxification agents and emergency drug product lines, as well as complex formulations and specialty 505(b)(2) products. The approval of hydrochloride injection of nalmefene by the FDA in November 2023 marks the company's first product for international markets. The approval of hydrochloride injection of nicardipine in September 2024 is also expected to contribute to recent performance. With the expected volume growth of these products, the company's export business is anticipated to enter a rapid growth phase [12][13]. - Earnings forecasts indicate that the company's revenue for 2024-2026 is expected to be 1.365 billion yuan, 1.706 billion yuan, and 2.121 billion yuan, with year-on-year growth rates of 22.2%, 25.0%, and 24.3%, respectively. The net profit attributable to shareholders is projected to be 276 million yuan, 337 million yuan, and 424 million yuan, with year-on-year growth rates of 21.7%, 22.2%, and 25.9%. Based on the closing price on October 15, the corresponding PE ratios are 23.3, 19.0, and 15.1, leading to the initial coverage rating of "Accumulate" [13][14]. Summary by Sections Section 1: Impact of Centralized Procurement - The negative impact of price reductions on performance has been fully digested, and existing key products are expected to maintain steady revenue growth. New products are beginning to contribute to revenue growth, with several recent approvals showing strong potential [6][10]. Section 2: Export Product Lineup - The company is expanding its international presence with a focus on high-barrier products. The approval of key products by the FDA is expected to significantly enhance revenue from exports [12][13]. Section 3: Earnings Forecasts - Revenue and net profit projections for the next three years indicate robust growth, supported by new product launches and market expansion strategies [13][14].

北京植德律师事务所 关于成都苑东生物制药股份有限公司 2024 年第一次临时股东大会的 法律意见书 植德京(会)字[2024]0134 号 二〇二四年十月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel)：010-56500900 传真(Fax)：010-56500999 www.meritsandtree.com 北京植德律师事务所 关于成都苑东生物制药股份有限公司 2024 年第一次临时股东大会的 法律意见书 植德京(会)字[2024]0134 号 致：成都苑东生物制药股份有限公司（贵公司） 北京植德律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2024 年第一次临时股东大会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人 ...

证券代码：688513 证券简称：苑东生物 公告编号：2024-078 成都苑东生物制药股份有限公司 | 1、出席会议的股东和代理人人数 | 138 | | --- | --- | | 普通股股东人数 | 138 | | 2、出席会议的股东所持有的表决权数量 | 86,299,957 | | 普通股股东所持有表决权数量 | 86,299,957 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 49.5105 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 49.5105 | 注：计算出席会议的股东（普通股股东）所持有的表决权数量占公司表决权数量的比例已剔 除本次股权登记日登记在册的公司股票回购专户所持有的股份。 （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 2024 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间 ...